What gets measured
Blood panels and screens
Direct-to-consumer panels, reference ranges, and the difference between an abnormal number and a problem.
- Direct-to-consumer panels
- Reference intervals
- Measurement error
- Repeat testing
Testing moved out of the clinic and into the shop. These three sections follow what that changed: the panels, the age estimates, and the rules.
What gets measured
Direct-to-consumer panels, reference ranges, and the difference between an abnormal number and a problem.
Age estimates
Epigenetic clocks, pace-of-ageing measures, and the reliability problem underneath both.
Rules and gaps
Who is allowed to sell a test, what gets reviewed before sale, and where the gaps sit.
Each piece gets re-read when new trial data lands. Filter by section to see what changed.
A 2026 reliability study found that DNA methylation clocks are highly reproducible in the lab and considerably less stable in the person. That distinction matters enormously.
Direct-to-consumer panels sell breadth. Breadth without a question produces incidental abnormalities and follow-up that leads nowhere.
A device class built for diabetes management is now a pharmacy purchase for people with no diagnosis. The clearance covers the sensor, not the interpretation.
Methylation clocks, telomere length, blood biomarker algorithms, glycan analysis, and composite scores measure different things. Disagreement between them is expected, not anomalous.
Normal is a statistical construction built from a reference population. If you do not resemble that population, the range is a rough guide at best.
Cohort data points at the same short list every time, and none of it is available in a bottle.
Stories in progress, with roughly where they stand. Vote to tell the desk what to prioritise.
We publish clinicians, laboratory scientists, epidemiologists, and health policy researchers. Every submission is checked against the primary source.
Sensitivity, specificity, reference intervals, and measurement error. The unglamorous statistics that decide whether a result means anything.
What a clinician does with a number, and where consumer reporting of the same number diverges from that.
Clearance pathways, laboratory-developed tests, direct-to-consumer rules, and enforcement.
Longer pieces we keep sending people back to.
A 2026 reliability study found that DNA methylation clocks are highly reproducible in the lab and considerably less stable in the person. That distinction matters enormously.
Methylation clocks, telomere length, blood biomarker algorithms, glycan analysis, and composite scores measure different things. Disagreement between them is expected, not anomalous.
Almost every clinically useful thing a consumer test can tell you comes from the second measurement, not the first.
Keeps pages loading and remembers this choice. Always on.
Anonymous page counts so we know which articles to update first.
Remembers your sections so the homepage leads with them.